Divine Aleru, Microbiome Medicine Research Coordinator

This study identifies the role of Fusobacterium nucleatum Fap2 in mediating bacterial enrichment in colorectal cancer by binding to tumor-expressed Gal-GalNAc. Targeting this interaction could reduce Fusobacterium’s potentiation of CRC, offering new therapeutic and diagnostic opportunities.

This review explores Fusobacterium nucleatum’s role as a transboundary pathogen in diseases like colorectal cancer and inflammatory bowel disease, highlighting its virulence factors, immune modulation, and complex microbial interactions. It offers insights into potential therapeutic strategies targeting this pathogen and its microbial networks.

This review discusses Fusobacterium nucleatum’s pivotal role in diseases like colorectal cancer and inflammatory bowel disease, emphasizing its pathogenic mechanisms, including immune evasion and tumor progression, and exploring novel diagnostic and therapeutic approaches targeting this bacterium.

This study explores the prevalence of Fusobacterium nucleatum in primary and secondary endodontic infections, highlighting its association with clinical symptoms like pain and swelling. PCR detection showed higher prevalence, emphasizing the pathogen’s role and the need for focused endodontic treatments.

This review shows that dietary polyphenols selectively increase Akkermansia muciniphila, improving gut barrier function and metabolic outcomes through microbiome-mediated mechanisms rather than direct antioxidant effects.

This review positions Akkermansia muciniphila as a key regulator of oxidative stress through mucin metabolism, bioactive proteins, and gut–organ signaling. Its clinical impact spans metabolic, inflammatory, and neurodegenerative conditions, with benefits strongly dependent on strain and host context.

This systematic review evaluated how bioactive compounds, including dietary fibers, polyphenols, antioxidants, human milk oligosaccharides, and selected pharmaceuticals, influence the abundance and functional activity of Akkermansia muciniphila in the gut. Following PRISMA 2020 guidelines, the authors synthesized experimental evidence from 2004 to 2025 to clarify mechanisms through which these compounds modulate A. […]

This review summarizes evidence that diet, prebiotics, and drugs such as metformin can increase Akkermansia muciniphila, a mucus-associated bacterium linked to improved metabolic health and reduced inflammation.

This study shows that live Akkermansia muciniphila protects against diet-induced obesity by selectively remodeling intestinal mucus glycan composition and barrier gene expression, rather than altering overall microbiome structure.

This study shows how gut bacterial mucinases precisely cleave O-glycan-rich glycoproteins using specialized structural adaptations, enabling controlled mucus turnover while preserving barrier function and explaining how mucin-degrading microbes can be beneficial or harmful depending on context.

This study shows that Akkermansia muciniphila uses dietary polyphenols as iron carriers, enabling growth under iron limitation and outcompeting pathogenic bacteria through advanced iron acquisition systems.

This review highlights Akkermansia-derived extracellular vesicles as powerful regulators of gut barrier function, immune balance, metabolism, and cancer response, positioning them as promising cell-free microbiome therapeutics.

This study shows that Akkermansia muciniphila survives gastrointestinal stress through aggregation, adheres preferentially to mucus-secreting intestinal cells, and interacts with human mucins via specific proteins, supporting its therapeutic potential while highlighting dose-dependent safety considerations.

This review explains how Akkermansia muciniphila proteins, not just the bacterium itself, regulate immunity, metabolism, gut barrier integrity, cancer response, and neuroinflammation, highlighting their emerging role as next-generation postbiotic therapeutics.

This review explains how mucin-degrading gut bacteria regulate barrier integrity, immunity, and disease risk in a context-dependent manner. It highlights why microbes such as Akkermansia muciniphila can be protective or harmful depending on diet, strain, and host immune status.

This study shows that Akkermansia muciniphila produces a uniquely structured lipooligosaccharide that preferentially activates anti-inflammatory TLR2 signaling while limiting TLR4-driven endotoxin responses. The findings explain how this Gram-negative symbiont supports immune balance and metabolic health.

This review explores when mucus degradation by Akkermansia muciniphila supports gut health and when it harms barrier integrity. Evidence shows its effects depend on host context, microbial balance, and mucus renewal capacity, reframing it as a condition-dependent microbiome signal rather than a universal probiotic.

This study shows that excessive Akkermansia muciniphila colonization damages the intestinal mucus barrier and tight junctions in colorectal cancer models, worsening inflammation and disease progression. Findings highlight its role as a context-dependent microbe rather than a universally beneficial probiotic.

This review summarizes evidence that Akkermansia muciniphila reduces inflammation and improves metabolic health by strengthening the gut barrier and regulating immune signaling. Findings support its role as a next-generation probiotic for obesity, diabetes, and related inflammatory conditions.

This review shows that Akkermansia muciniphila protects against bacterial and viral infections by strengthening gut barriers and regulating systemic immunity. Evidence supports its role as a next-generation probiotic with effects extending beyond metabolism into infection and immune resilience.

This study shows that antibiotics can select Akkermansia muciniphila variants that lose their ability to protect against obesity and metabolic dysfunction. The findings reveal a direct mechanistic link between antibiotic exposure, altered microbiome function, and chronic metabolic disease risk.

This study shows that human-derived Akkermansia muciniphila strains carry limited, mostly nonfunctional antibiotic resistance traits. Phenotypic testing confirms low risk of transferable resistance, supporting its safety as a next-generation probiotic and microbiome biomarker.

This review explains how Akkermansia muciniphila supports gut barrier integrity, immune balance, and metabolic health. Evidence highlights its role as a key microbiome signal across obesity, inflammation, and aging, with postbiotic strategies showing strong clinical promise.

This review synthesizes evidence showing Akkermansia muciniphila supports gut barrier integrity, immune balance, and metabolic health through mucin degradation, SCFA production, and bioactive proteins, with emerging human trials confirming safety and therapeutic promise.